Generate a tailored SOP for Dr. Colin Ross. Improve your application with a focused, well-structured draft.
Colin Ross is a Professor and Associate Dean of Research at the Faculty of Pharmaceutical Sciences, University of British Columbia. His research focuses on the development of new medicines and optimizing their safe and effective use to treat diseases, with a particular emphasis on pediatric cancer and genetic disorders. Dr. Ross has published over 220 scientific articles in prestigious medical journals, with a significant h-index of 58 and more than 12,500 citations. He plays a key role in the Canadian Pharmacogenomics Network for Drug Safety, where he contributes to identifying genetic risk factors for adverse drug reactions. Additionally, Dr. Ross is known for his work on Glybera, the first gene therapy to receive formal regulatory approval, and continues to develop novel therapeutics for gene editing to treat genetic diseases. He is also an external scientific advisor for the NIH’s “TARGETED Challenge” Genome Editor Delivery program, aimed at addressing challenges in gene editor delivery to target tissues in the brain.
University of British Columbia • Vancouver, BC, Canada
Research and teaching in the field of pharmaceutical sciences.
Offers course-only and thesis routes. Focus areas include philosophy of science, mind, ethics, and Asian philosophy.